{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:56:28Z","timestamp":1773662188604,"version":"3.50.1"},"reference-count":209,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1016\/s1368-7646(03)00026-8","type":"journal-article","created":{"date-parts":[[2003,4,24]],"date-time":"2003-04-24T23:51:23Z","timestamp":1051228283000},"page":"111-127","source":"Crossref","is-referenced-by-count":75,"title":["Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences"],"prefix":"10.1016","volume":"6","author":[{"given":"Henk J","family":"Broxterman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lankelma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaas","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S1368-7646(03)00026-8_BIB1","first-page":"3352","article-title":"Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin","volume":"5","author":"Abolhoda","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB2","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1038\/sj.onc.1205838","article-title":"The radioprotective effect of the 24 FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit","volume":"21","author":"Ader","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB3","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2002.20.19.3944","article-title":"Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!","volume":"20","author":"Alberts","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB4","first-page":"5761","article-title":"Extensive contribution of the multidrug transporters P-glycoprotein and MRP1 to basal drug resistance","volume":"60","author":"Allen","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB5","first-page":"6101","article-title":"An informatics approach identifying markers of chemosensitivity in human cancer cell lines","volume":"60","author":"Amundson","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB6","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/sj.onc.1204554","article-title":"Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells","volume":"20","author":"Aoudjit","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB8","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.2002.02.069","article-title":"Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III trial-08923","volume":"20","author":"Ardizzoni","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB9","doi-asserted-by":"crossref","first-page":"44236","DOI":"10.1074\/jbc.M207578200","article-title":"Synthetic Smac\/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP in situ","volume":"277","author":"Arnt","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0168-3659(01)00308-X","article-title":"Determinants of drug delivery and transport to solid tumors","volume":"74","author":"Au","year":"2001","journal-title":"J. Controlled Release"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB11","first-page":"1996","article-title":"Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer","volume":"62","author":"Baker","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB12","first-page":"3346","article-title":"Drug resistance: still on the learning curve","volume":"5","author":"Bates","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB13","first-page":"5275","article-title":"CD44 survival pathway triggers chemoresistance via Lyn kinase and phosphinositide 3-kinase\/Akt in colon carcinoma cells","volume":"61","author":"Bates","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB14","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB15","first-page":"7501","article-title":"Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo","volume":"61","author":"Bello","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0165-6147(02)02039-4","article-title":"Apoptosis: coming to terms with biological diversity","volume":"23","author":"Beranek","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB17","first-page":"1174","article-title":"Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies","volume":"30","author":"Biedler","year":"1970","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB18","doi-asserted-by":"crossref","first-page":"11995","DOI":"10.1074\/jbc.273.20.11995","article-title":"P53 inhibits hypoxia-inducible factor-stimulated transcription","volume":"273","author":"Blagosklonny","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB19","first-page":"6938","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1054\/drup.2001.0187","article-title":"Does resistance to apoptosis affect clinical response to antitumor drugs?","volume":"4","author":"Borst","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1054\/drup.2001.0193","article-title":"Apoptosis: mediator or mode of cell killing by anticancer agents?","volume":"4","author":"Brown","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1054\/drup.2001.0216","article-title":"Cancer research 2001: drug resistance, new targets and drug combinations","volume":"4","author":"Broxterman","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1054\/drup.1999.0081","article-title":"Direct activation of caspases by RGD-peptides may increase drug sensitivity of tumor cells","volume":"2","author":"Broxterman","year":"1999","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB24","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ijc.2910610622","article-title":"Correlation between functional and molecular analysis of MDR1 P-glycoprotein in human solid-tumor xenografts","volume":"61","author":"Broxterman","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB25","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/sj.leu.2400685","article-title":"Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia","volume":"11","author":"Broxterman","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.leu.2401331","article-title":"Do P-glycoprotein and major vault protein (MVP\/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?","volume":"13","author":"Broxterman","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/sj.leu.2401796","article-title":"P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin\/cytosine arabinoside-based induction therapy","volume":"14","author":"Broxterman","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB28","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S1470-2045(02)00938-5","article-title":"What went wrong with Iressa?","volume":"3","author":"Burton","year":"2002","journal-title":"Lancet Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB29","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1038\/sj.onc.1203078","article-title":"Role of p53 and p21waf1\/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs","volume":"18","author":"Chang","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB30","first-page":"3006","article-title":"Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides","volume":"7","author":"Chatterjee","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1368-7646(02)00003-1","article-title":"Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase\/Akt pathway","volume":"5","author":"Cheng","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB32","first-page":"3387","article-title":"Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene","volume":"62","author":"Comerford","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB33","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0006-2952(02)01268-6","article-title":"Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation or p53 status","volume":"64","author":"Coleman","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB34","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/00001756-200211150-00014","article-title":"Localisation of breast cancer resistance protein in microvessel endothelium of human brain","volume":"13","author":"Cooray","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1172\/JCI0215223","article-title":"Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration","volume":"110","author":"Curnis","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1054\/drup.1999.0097","article-title":"The tumor microenvironment as a determinant of drug response and resistance","volume":"2","author":"Dalton","year":"1999","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB37","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.7521539","article-title":"Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1","volume":"265","author":"Dameron","year":"1994","journal-title":"Science"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB38","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0005-2736(73)90191-0","article-title":"Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells","volume":"323","author":"Dan\u00f8","year":"1973","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1023\/A:1020647211557","article-title":"Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis","volume":"7","author":"Dartsch","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB40","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1021\/jm9910472","article-title":"Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin","volume":"42","author":"De Groot","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB41","first-page":"901","article-title":"Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug","volume":"1","author":"De Groot","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB42","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/81351","article-title":"A peptide-doxorubicin \u201cprodrug\u201d activated by prostate-specific antigen selectively kills prostate-tumor cells positive for prostate-specific antigen in vivo","volume":"6","author":"DeFeo-Jones","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/mol.61.3.524","article-title":"Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation","volume":"61","author":"Del Bufalo","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1040-8428(00)00086-X","article-title":"Multicellular resistance: a paradigm for clinical resistance?","volume":"36","author":"Desoize","year":"2000","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB45","first-page":"1533","article-title":"Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma","volume":"4","author":"Dexter","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/sonc.2002.33528","article-title":"High-dose chemotherapy in breast cancer: where are we now?","volume":"29","author":"Dicato","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jcp.10152","article-title":"Overexpression of the 18 and 22\/24 kDa FGF-2 isoforms results in differential drug resistance and amplification potential","volume":"193","author":"Dini","year":"2002","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB48","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1200\/JCO.2002.07.001","article-title":"Characterization of a novel prostate-specific antigen-activated peptide\u2013doxorubicin conjugate in patients with prostate cancer","volume":"20","author":"DiPaola","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB49","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1054\/drup.2001.0219","article-title":"Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives","volume":"4","author":"Dormond","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB50","first-page":"2327","article-title":"CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity","volume":"62","author":"Dubois","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB51","first-page":"3495","article-title":"Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro","volume":"41","author":"Durand","year":"1981","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB52","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02897199","article-title":"Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage?","volume":"26","author":"Durand","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1054\/drup.2001.0214","article-title":"Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy","volume":"4","author":"Fan","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1097-0215(20010701)93:1<114::AID-IJC1309>3.0.CO;2-J","article-title":"Determining MDR1\/P-glycoprotein expression in breast cancer","volume":"93","author":"Faneyte","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1054\/drup.2001.0207","article-title":"The role of prodrug therapy in the treatment of cancer","volume":"4","author":"Ferguson","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1368-7646(02)00119-X","article-title":"P53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53","volume":"5","author":"Fojo","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB57","first-page":"2388","article-title":"Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular spheroids","volume":"57","author":"Frankel","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB58","first-page":"3719","article-title":"Lack of multicellular drug resistance observed in human ovarian and prostate treated with the proteasome inhibitor PS-431","volume":"6","author":"Frankel","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB59","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1073\/pnas.87.17.6698","article-title":"Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines","volume":"87","author":"Fridman","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0955-0674(00)00251-9","article-title":"Anoikis mechanisms","volume":"13","author":"Frisch","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1054\/drup.2000.0142","article-title":"In vivo veritas: Bcl-2 and Bcl-XL mediate tumor cell resistance to chemotherapy","volume":"3","author":"Fujita","year":"2000","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-5793(02)03262-3","article-title":"CD44 signaling through focal adhesion kinase and its anti-apoptotic effect","volume":"528","author":"Fujita","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB63","first-page":"843","article-title":"FGF expression correlates with paclitaxel resistance in human tumors","volume":"41","author":"Gan","year":"2000","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/jnci\/94.2.82","article-title":"Could less be more? Low-dose chemotherapy goes on trial","volume":"94","author":"Garber","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB65","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0959-8049(02)00490-2","article-title":"MDR1 inhibition: less resistance or less relevance?","volume":"38","author":"Garraway","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0002-9440(10)63809-6","article-title":"Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy","volume":"162","author":"Gee","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB67","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1368764602001061","article-title":"Clinical cancer research 2002: new agents and therapies","volume":"5","author":"Gietema","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4613-1601-5_2","article-title":"Mathematical models of drug resistance and chemotherapy effects","volume":"48","author":"Goldie","year":"1989","journal-title":"Cancer Treatment Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1054\/drup.2001.0192","article-title":"Mitochondria as targets for established and novel anti-cancer agents","volume":"4","author":"Grad","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/379088a0","article-title":"Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors","volume":"379","author":"Graeber","year":"1996","journal-title":"Nature"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/86.13.975","article-title":"Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents","volume":"86","author":"Graham","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.10907","article-title":"Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)","volume":"104","author":"Grant","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB73","first-page":"3776","article-title":"Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications","volume":"59","author":"Griffon-Etienne","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB74","doi-asserted-by":"crossref","first-page":"8650","DOI":"10.1074\/jbc.275.12.8650","article-title":"CD95 (Fas\/Apo-1) signals ceramide generation independent of the effector stage of apoptosis","volume":"275","author":"Grullich","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB75","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis","volume":"105","author":"Hanahan","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB76","first-page":"417","article-title":"In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton","volume":"21","author":"Hayot","year":"2002","journal-title":"Int. J. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB77","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/sj.onc.1203782","article-title":"Adhesion to fibronectin via \u03b21 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance CAM-DR","volume":"19","author":"Hazlehurst","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB78","first-page":"4458","article-title":"Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor","volume":"59","author":"Heijn","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB79","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1054\/drup.2001.0208","article-title":"Potential and caveats of TRAIL in cancer therapy","volume":"4","author":"Held","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB80","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s002800050773","article-title":"Paclitaxel\/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models","volume":"41","author":"Herbst","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB81","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1200\/JCO.2002.04.006","article-title":"Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer","volume":"20","author":"Herbst","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB82","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1242\/jcs.00153","article-title":"Caspase-dependent initiation of apoptosis and necrosis by the FAS receptor in lymphoid cells: onset of necrosis with delayed ceramide increase","volume":"115","author":"Hetz","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB83","first-page":"6410","article-title":"Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors","volume":"62","author":"Hiltunen","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB84","first-page":"1191","article-title":"Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (taxotere): association with impaired repositioning of the microtubule organizing center","volume":"1","author":"Hotchkiss","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB85","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1054\/bjoc.2000.1640","article-title":"A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumor-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer","volume":"84","author":"Houba","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB86","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0002-9440(10)64467-7","article-title":"Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer","volume":"161","author":"Hu","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB87","first-page":"769","article-title":"Relationship of XIST expression and responses of ovarian cancer to chemotherapy","volume":"1","author":"Huang","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB88","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/nm0902-918","article-title":"A reevaluation of integrins as regulators of angiogenesis","volume":"8","author":"Hynes","year":"2002","journal-title":"Nat. Med."},{"issue":"Suppl. 16","key":"10.1016\/S1368-7646(03)00026-8_BIB89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37265","article-title":"Tumor angiogenesis and accessibility: role of vascular endothelial growth factor","volume":"29","author":"Jain","year":"2002","journal-title":"Sem. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB90","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(00)03207-4","article-title":"Chemosensitisation of malignant melanoma by bcl-2 oligodeoxynucleotides","volume":"356","author":"Jansen","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB91","first-page":"6146","article-title":"Tumor imaging with radiolabeled \u03b1\u03bd\u03b23 integrin binding peptides in a nude mouse model","volume":"62","author":"Janssen","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB92","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in chinese hamster ovary cells","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB93","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0959-8049(02)00013-8","article-title":"Effects of combination anti-vascular endothelial growth factor receptor andanti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model","volume":"38","author":"Jung","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB94","first-page":"1","article-title":"Targeting the epidermal growth factor receptor: apoptosis takes center stage","volume":"63","author":"Kari","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB95","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/316820a0","article-title":"Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies","volume":"316","author":"Kartner","year":"1985","journal-title":"Nature"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/bies.950130106","article-title":"Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents","volume":"13","author":"Kerbel","year":"1991","journal-title":"Bioessays"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB97","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB98","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/cdd.1987.4.63","article-title":"In vitro chemosensitivity testing using the multicellular tumor spheroid model","volume":"4","author":"Kerr","year":"1987","journal-title":"Cancer Drug Deliv."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB99","first-page":"5597","article-title":"An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy","volume":"62","author":"Keyes","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB100","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.1073\/pnas.172398399","article-title":"Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma","volume":"99","author":"Kim","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB101","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1172\/JCI0214268","article-title":"Inhibition of endothelial cell survival and angiogenesis by protein kinase A","volume":"110","author":"Kim","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB102","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature01254","article-title":"Computational systems biology","volume":"420","author":"Kitano","year":"2002","journal-title":"Nature"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB103","first-page":"221","article-title":"Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts","volume":"8","author":"Klement","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB104","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1023\/A:1020091226673","article-title":"Apoptotic markers for tumor recurrence: a minireview","volume":"7","author":"Konstantinidou","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB105","doi-asserted-by":"crossref","first-page":"8683","DOI":"10.1038\/sj.onc.1205939","article-title":"In vitro chemo- and radiosensitivity in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways","volume":"21","author":"Kraus","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB106","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1054\/drup.2000.0176","article-title":"Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents","volume":"4","author":"Krystal","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB107","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.20.6.1657","article-title":"Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors","volume":"20","author":"Kuenen","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB108","unstructured":"Kuenen, B.C., Tabernero, J., Baselga, J., Cavalli, F., Conte, P.F., Seeber, S., et al., in press. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB109","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0890-6238(98)00027-6","article-title":"Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice","volume":"12","author":"Lankas","year":"1998","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB110","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2174\/1381612023393512","article-title":"Tissue transport of anti-cancer drugs","volume":"8","author":"Lankelma","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB111","first-page":"1703","article-title":"Doxorubicin gradients in human breast cancer","volume":"5","author":"Lankelma","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/cbr.1999.14.31","article-title":"Paclitaxel (taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer","volume":"14","author":"Lau","year":"1999","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB113","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.V98.4.913","article-title":"Signaling pathways activated by daunorubicin","volume":"98","author":"Laurent","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB114","first-page":"1303","article-title":"Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer","volume":"56","author":"Lee","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB115","doi-asserted-by":"crossref","first-page":"28253","DOI":"10.1074\/jbc.273.43.28253","article-title":"Paclitaxel (taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK\/SAPK)","volume":"273","author":"Lee","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB116","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1172\/JCI0216493","article-title":"Clinical use of TNF revisited: improving penetration of anticancer agents by increasing vascular permeability","volume":"110","author":"Lejeune","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB118","doi-asserted-by":"crossref","first-page":"46248","DOI":"10.1074\/jbc.M209288200","article-title":"Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins \u03b1\u03bd\u03b23 and \u03b16\u03b21 in human umbilical vein endothelial cells","volume":"277","author":"Leu","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB119","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.062698499","article-title":"Integrins regulate the apoptotic response to DNA damage through modulation of p53","volume":"99","author":"Lewis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB120","first-page":"3570","article-title":"Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor antisense","volume":"8","author":"Li","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB121","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/mvre.1998.2140","article-title":"Effect of local anti-VEGF antibody treatment on tumor microvessel permeability","volume":"57","author":"Lichtenbeld","year":"1999","journal-title":"Microvasc. Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB123","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","article-title":"Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study","volume":"98","author":"List","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB124","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1073\/pnas.0334858100","article-title":"Multiple mutations and cancer","volume":"100","author":"Loeb","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1054\/drup.2001.0201","article-title":"Anthracycline drug targeting: cytoplasmic versus nuclear\u2014a fork in the road","volume":"4","author":"Lothstein","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB126","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","article-title":"Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth","volume":"7","author":"Lyden","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB127","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1126\/science.1065298","article-title":"Tumstatin, an endothelial cell-specific inhibitor of protein synthesis","volume":"295","author":"Maeshima","year":"2002","journal-title":"Science"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1054\/drup.2000.0138","article-title":"Liposomal formulations of anticancer drug: selectivity and effectiveness","volume":"3","author":"Massing","year":"2000","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB129","doi-asserted-by":"crossref","first-page":"27757","DOI":"10.1074\/jbc.M102014200","article-title":"A signaling pathway from the \u03b15\u03b21 and \u03b1\u03bd\u03b23 integrins that elevates bcl-2 transcription","volume":"276","author":"Matter","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB130","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","article-title":"Redefining the target: chemotherapeutics as antiangiogenics","volume":"19","author":"Miller","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-5793(02)03432-4","article-title":"New advances on structural and biological functions of ceramide in apoptotic\/necrotic cell death and cancer","volume":"530","author":"Mimeault","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB132","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1054\/drup.2000.0150","article-title":"Anti-angiogenic therapy: basic concepts and importance of dosing schedules in clinical trials","volume":"3","author":"Mross","year":"2000","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB133","first-page":"633","article-title":"Modulating multidrug resistance: can we target this therapy?","volume":"8","author":"Murren","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB134","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9440(10)64742-6","article-title":"Control of apoptosis during angiogenesis by survivin expression in endothelial cells","volume":"156","author":"O\u2019Connor","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB135","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1054\/drup.2001.0225","article-title":"Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance","volume":"4","author":"Ogretmen","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB136","doi-asserted-by":"crossref","first-page":"24901","DOI":"10.1074\/jbc.M100314200","article-title":"Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells","volume":"276","author":"Ogretmen","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB137","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1054\/drup.2001.0181","article-title":"Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential","volume":"4","author":"Olie","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB138","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1368-7646(02)00050-X","article-title":"Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives","volume":"5","author":"Ortiz","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(01)80010-5","article-title":"Involvement of platelet-derived growth factor in disease: development of specific antagonists","volume":"80","author":"\u00d6stman","year":"2001","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB140","doi-asserted-by":"crossref","first-page":"44317","DOI":"10.1074\/jbc.M205273200","article-title":"Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin","volume":"277","author":"Panaretakis","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB141","doi-asserted-by":"crossref","first-page":"12040","DOI":"10.1074\/jbc.M109006200","article-title":"Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway","volume":"277","author":"Pardo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB142","first-page":"1523","article-title":"Neutralizing antibodies against epidermal growth factor and ErbB-2\/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors","volume":"151","author":"Petit","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB143","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB144","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1368-7646(98)80216-1","article-title":"High-dose chemotherapy: how resistant is breast cancer?","volume":"1","author":"Pusztai","year":"1998","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","article-title":"Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha","volume":"14","author":"Ravi","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB146","first-page":"963","article-title":"Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis","volume":"57","author":"Relf","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB147","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1368764602001103","article-title":"Tumor senescence as a determinant of drug response in vivo","volume":"5","author":"Roninson","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB148","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1054\/drup.2001.0213","article-title":"If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells","volume":"4","author":"Roninson","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB149","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nm0498-408","article-title":"Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma","volume":"4","author":"R\u00fcegg","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1054\/drup.2000.0154","article-title":"Tumor necrosis factor: clinical use and mechanisms of action","volume":"3","author":"R\u00fcegg","year":"2000","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB151","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1368-7646(98)80039-3","article-title":"Future perspectives for the development of P-glycoprotein modulators","volume":"1","author":"Sandor","year":"1998","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB152","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2002.01.033","article-title":"Mechanisms and future directions for angiogenesis-based cancer therapies","volume":"20","author":"Scappaticci","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB153","first-page":"1242","article-title":"Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction therapy","volume":"63","author":"Schimmer","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB154","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1368-7646(02)00004-3","article-title":"EGF receptor targeting in therapy-resistant human tumors","volume":"5","author":"Schmidt","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1054\/drup.2001.0188","article-title":"Apoptosis is critical for drug response in vivo","volume":"4","author":"Schmitt","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB156","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0092-8674(02)00734-1","article-title":"A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy","volume":"109","author":"Schmitt","year":"2002","journal-title":"Cell"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB157","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1054\/drup.1999.0100","article-title":"Small cell and its stroma: determinant of pan-resistance?","volume":"2","author":"Sehested","year":"1999","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB158","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/9511","article-title":"Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo","volume":"5","author":"Sehti","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB159","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/jnci\/87.9.687","article-title":"Re: rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor agents","volume":"87","author":"Sergeeva","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB160","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.cgt.7700361","article-title":"Downmodulation of bFGF-binding protein expression following restoration of p53 function","volume":"8","author":"Sherif","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB161","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ijc.10668","article-title":"Hyaluronidase reduces human breast cancer xenografts in SCID mice","volume":"102","author":"Shuster","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB162","first-page":"1077","article-title":"Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor","volume":"40","author":"Skovsgaard","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB163","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-6147(00)01867-8","article-title":"Apoptosis: a guide for the perplexed","volume":"23","author":"Sloviter","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB164","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/emboj\/18.4.882","article-title":"Role of \u03b1\u03bd\u03b23 integrin in the activation of vascular endothelial growth factor-2","volume":"18","author":"Soldi","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB165","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1073\/pnas.140210697","article-title":"Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs","volume":"97","author":"Song","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB166","first-page":"6145","article-title":"Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases","volume":"61","author":"Song","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB167","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0304-3835(98)00199-2","article-title":"Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors","volume":"131","author":"St. Croix","year":"1998","journal-title":"Cancer Lett."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB168","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jnci\/86.13.953","article-title":"An added dimension: will three-dimensional cultures improve our understanding of drug resistance?","volume":"86","author":"Steeg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB169","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1242\/jcs.00071","article-title":"Get a ligand, get a life: integrins, signaling and cell survival","volume":"115","author":"Stupack","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.200106070","article-title":"Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins","volume":"155","author":"Stupack","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB171","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1172\/JCI118808","article-title":"Suppression of p53 activity and p21WAF1\/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis","volume":"98","author":"Stromblad","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB172","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0360-3016(79)90643-6","article-title":"Resistance to adriamycin in multicellular spheroids","volume":"5","author":"Sutherland","year":"1979","journal-title":"Int. J. Radiat. Oncol. Biophys."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB173","first-page":"3369","article-title":"The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors","volume":"61","author":"Sweeney","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB174","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1054\/drup.2001.0218","article-title":"Breast cancer response to aclitaxel in vivo","volume":"4","author":"Symmans","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB175","first-page":"878","article-title":"Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy","volume":"8","author":"Tannock","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB176","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/92.1.18","article-title":"Epigenetic determinants of resistance to etoposide regulation of Bcl-XL and Bax by tumor microenvironmental factors","volume":"92","author":"Taylor","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB177","first-page":"6289","article-title":"Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats","volume":"62","author":"Tei","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB178","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1368-7646(98)80215-X","article-title":"Role of angiogenesis in the response to anticancer therapies","volume":"1","author":"Teicher","year":"1998","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB179","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.2108497","article-title":"Tumor resistance to alkylating agents by mechanisms operative only in vivo","volume":"247","author":"Teicher","year":"1990","journal-title":"Science"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB180","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.6494917","article-title":"Effect of cell\u2013cell interaction on drug sensitivity and growth of drug-sensitive and-resistant tumor cells in spheroids","volume":"226","author":"Tofilon","year":"1984","journal-title":"Science"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB181","first-page":"2506","article-title":"Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production","volume":"6","author":"Tortora","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB182","first-page":"853","article-title":"MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors","volume":"149","author":"Toth","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB183","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1073\/pnas.072586399","article-title":"A role for surviving in chemoresistance of endothelial cells mediated by VEGF","volume":"99","author":"Tran","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB184","first-page":"2843","article-title":"Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies","volume":"61","author":"Trouet","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB185","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/sj.leu.2402245","article-title":"Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukaemia","volume":"15","author":"Van der Pol","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB186","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1054\/bjoc.1999.1027","article-title":"TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumor effects","volume":"82","author":"Van der Veen","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB187","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0006-2952(01)00928-5","article-title":"A doxorubicin\u2013CNGRC\u2013peptide conjugate with prodrug properties","volume":"63","author":"Van Hensbergen","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB188","first-page":"3747","article-title":"Soluble aminopeptidase N\/CD13 in malignant and nonmalignant effusions and intratumoral fluid","volume":"8","author":"Van Hensbergen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB189","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/oxfordjournals.annonc.a057825","article-title":"Differentiation dependent expression of P-glycoprotein in the normal and neoplastic kidney","volume":"2","author":"Van Kalken","year":"1991","journal-title":"Ann. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB190","first-page":"2187","article-title":"Platelet: transporter of vascular endothelial growth factor","volume":"3","author":"Verheul","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB191","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1054\/drup.2001.0206","article-title":"Clinical cancer research 2001: new agents and therapies","volume":"4","author":"Verweij","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB192","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria-Petit","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB193","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/jnci\/94.19.1494","article-title":"Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts","volume":"94","author":"Wang","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB194","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1535-6108(02)00125-3","volume":"2","author":"Weaver","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1054\/drup.2001.0180","article-title":"Mechanisms of resistance: imatinib (STI571) in preclinical models and in leukemia patients","volume":"4","author":"Weisberg","year":"2001","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB196","first-page":"670","article-title":"The anthracyclines\u2014will we ever find a better doxorubicin","volume":"19","author":"Weiss","year":"1992","journal-title":"Sem. Oncol."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB197","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1368-7646(02)00120-6","article-title":"Activation of the PI3K\/Akt pathway and chemotherapeutic resistance","volume":"5","author":"West","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB198","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1021\/js980497z","article-title":"In vitro transepithelial drug transport by on-line measurement: cellular control of paracellular and transcellular transport","volume":"88","author":"Wielinga","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB199","first-page":"6698","article-title":"Candidate genes for cross-resistance against DNA-damaging drugs","volume":"62","author":"Wittig","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB200","first-page":"313","article-title":"PSA-specific and non-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites","volume":"29","author":"Wong","year":"2001","journal-title":"Drug Metab. Disp."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB201","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1242\/jcs.111.4.469","article-title":"The synergistic activity of \u03b1\u03bd\u03b23 integrin and PDGF receptor increases cell migration","volume":"111","author":"Woodard","year":"1998","journal-title":"J. Cell Sci."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB202","first-page":"1727","article-title":"Up-regulation of vascular endothelial growth factor in breast cancer cells by the Heregulin-\u03b21-activated signaling pathway enhances endothelial cell migration","volume":"61","author":"Xiong","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB203","first-page":"271","article-title":"MDR1 gene expression in primary and advanced breast cancer","volume":"79","author":"Yang","year":"1999","journal-title":"Lab. Investig."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB204","first-page":"3910","article-title":"Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and power blot","volume":"8","author":"Yoo","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB205","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1068327","article-title":"Effect of p53 status on tumor response to antiangiogenic therapy","volume":"295","author":"Yu","year":"2002","journal-title":"Science"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1368-7646(02)00049-3","article-title":"Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions","volume":"5","author":"Zaffaroni","year":"2002","journal-title":"Drug Resist. Update"},{"key":"10.1016\/S1368-7646(03)00026-8_BIB207","first-page":"3655","article-title":"Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression","volume":"60","author":"Zhang","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB208","doi-asserted-by":"crossref","first-page":"39777","DOI":"10.1074\/jbc.M203927200","article-title":"Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine","volume":"277","author":"Zhou","year":"2002","journal-title":"J. Biol.Chem."},{"key":"10.1016\/S1368-7646(03)00026-8_BIB209","first-page":"5139","article-title":"Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo","volume":"62","author":"Zitzmann","year":"2002","journal-title":"Cancer Res."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764603000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764603000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T06:41:23Z","timestamp":1682491283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764603000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":209,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["S1368764603000268"],"URL":"https:\/\/doi.org\/10.1016\/s1368-7646(03)00026-8","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}